FGU Flashcards
(101 cards)
Cervical polyp
benign overgrowth of connective tissue and epithelium of the cervix
What is the commonest kind of invasive breast cancer?
invasive ductal carcinoma
Her2 status
Refers to whether or not the carcinoma cells:
o EITHER over-express Her2 protein
o OR have HER2 gene amplification.
Without one of these the cancer is not a target for Herceptin
Her2 positive cancers have a worse prognosis
heterotopia
the presence of a particular tissue type at a non-physiological site
usually co-exists with original tissue in its correct anatomical location
e.g. ectopic breast tissue in the axilla
macromastia
Stromal overgrowth leading to excessive breast size
Acute mastitis
cellulitis associated with breast feeding
Skin fissuring may let bacteria in, and milk stasis favours growth, leading to infection of breast tissue
usually staphylococcus aureas
causes cardinal signs of inflammation + nipple discharge and fever
Idiopathic granulomatous mastitis
chronic inflammatory disease of the breast that can clinically mimic breast carcinoma
Distinct hard mass.
Do not excise
Exclude causes like sarcoidosis/TB
Characteristics of Fibrocystic change
most frequent benign breast condition
multifocal and bilateral
may cause breast tenderness
Cyclical Variation – Lumps tend to be bigger and more tender in latter half of menstrual cycle
Does not increase risk of cancer
Classification of Fibrocystic change
1) ‘non proliferative’ (with no significant excess risk of subsequent breast cancer)
2) ‘proliferative without atypia’, (up to 2-fold excess risk of breast cancer)
3) ‘proliferative with atypia’ (about 5-fold or more excess cancer risk, especially if there is a positive family history).
Adenosis
increase in glandular breast tissue
Microcalcifications may be observed on mammography
may cause a clinically suspicious mass.
Epithelial hyperplasia
Associated with increased cancer risk.
3 kinds:
1) Ductal hyperplasia of usual type
2) ‘Atypical ductal hyperplasia’ (ADH)
3) ductal carcinoma in situ (DCIS)
Lobular neoplasia
Associated with increased cancer risk.
- atypical lobular hyperplasia (ALH)
- lobular carcinoma in situ (LCIS)
The difference between ALH and LCIS is of extent and amount of cellular proliferation.
Radial scars
benign lesions
characterised by:
o a fibrotic and elastotic core
o trapped glands
o a pseudo-infiltrative appearance
Intraduct papilloma
benign
tumour of the epithelium lining the mammary ducts
under areola
causes bloody discharge from nipple
fibroadenomas
commonest in young women (teens - 30s).
Benign
hormone sensitive, and regresses after the menopause.
firm, non-tender, mobile lump
known as a “Breast mouse” because it is not tethered
Hamartoma of breast
rare, benign, tumour-like nodules composed of glandular, adipose and fibrous tissue
Risk factors for breast cancer
o earlier menarche o later menopause o being older at first pregnancy/childbirth o OCP use o HRT o Obesity o Tallness o denser breast tissue on mammography o alcohol o positive family history
Symptoms of possible breast cancer
- A new lump or thickening in breast or axilla.
- Altered shape, size or feel of the breast
- pain (not often)
Skin changes: o puckering o dimpling o 'peau d'orange' (skin oedema) o Rash o Redness o feels different.
Nipple changes:
o tethering/inversion
o discharge
o eczema-like changes in Paget’s disease.
Investigation of breast abnormalities
Clinical examination - inspection in different positions, palpation.
Imaging - ultrasound, X-ray mammography, MRI
Fine needle aspiration cytology
Core biopsy
Excisional biopsy - diagnostic, therapeutic, or both
Treatment of breast cancer
Usually wide local excision followed by radiotherapy
Larger cancers may still require mastectomy to achieve clear margins
Spread of breast cancer
tends to metastasise to lymph nodes of the axilla by lymphatic spread
Staging the axilla is important for prognosis and treatment. This is done by sentinel node biopsy
which breast carcinomas are likely to respond to endocrine treatment?
ER/PR positive
About 80% breast cancers overexpress oestrogen receptor (ER) and progesterone receptor (PR).
• e.g. Tamoxifen for breast cancer that is ER positive (predominantly an ER antagonist)
Which drugs can be used to prevent oestrogen stimulation of tumour growth in breast cancer?
aromatase inhibitors
prevent conversion of (adrenal) androgens to oestrogen
NB: cause osteoporosis
Are ER, PR and Her2 status more important as prognostic or predictive factors?
important for predicting likely response to endocrine and Her2-targeting therapies